NanoViricides to raise $2M in registered direct offering

Under the presumption of the agreement, the institution volition merchantability conscionable implicit 1.3 cardinal communal shares, oregon pre-funded warrants successful lieu thereof, unneurotic with accompanying warrants to acquisition an adjacent fig of communal shares.

Each warrant carries an workout terms of $1.75 per stock and volition expire 3 years from the day of issuance.

The financing comes arsenic the institution reported currency and currency equivalents of astir $3.38 cardinal arsenic of March 31, 2026.

NanoViricides said it has narrowed its near-term absorption to a Phase II objective proceedings of its pb cause candidate, NV-387, for the attraction of monkeypox successful the Democratic Republic of Congo. The section regulatory agency, ACOREP, has already approved the trial, and the institution said it is presently moving connected objective proceedings tract readiness.

In April, the US FDA granted NV-387 orphan cause designation for the attraction of measles. The institution has besides applied for orphan cause designation for MPox and smallpox indications and has filed for uncommon pediatric illness cause designation for measles, which could marque it eligible for a precedence reappraisal voucher upon imaginable cause approval.

NanoViricides said it has entree to an at-the-market communal banal installation with D Boral Capital and an disposable $3 cardinal enactment of recognition provided by laminitis and president Anil Diwan, connected which nary funds person been drawn.